Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Research runs each weekday at 8 a.m. Eastern Time. Channels update when qualifying developments are found. Editorial standards · RSS ↗
Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.
Vir Biotechnology announced that Phase 3 ECLIPSE 1 results for elebsiran plus tobevibart in chronic hepatitis delta will be presented on November 8, with an investor discussion on November 9. Elebsiran is an HBV-targeting siRNA; tobevibart is an antibody. The release announces the forthcoming readout and expanded Phase 2 presentations but does not disclose the Phase 3 numerical results.
Amphista announced an ASH oral presentation on AMX-883-mediated BRD9 degradation, describing disruption of hematopoietic transcriptional programs, myeloid differentiation, and reduced leukemic stem-cell frequency in experimental work. A separate abstract outlines the ongoing Phase 1 BRAMLIE study in AML and high-risk myelodysplastic syndrome. The announcement does not establish clinical efficacy for AMX-883.
Nurix announced updated Phase 1a/1b findings for its oral BTK degrader bexobrutideg (NX-5948) in relapsed or refractory CLL/SLL. The ASH presentation will include patients previously exposed to covalent BTK inhibitors and data at the recommended Phase 2 dose of 600 mg once daily. The release describes durable activity without providing numerical response rates.
Intellia's third-quarter update reports completed enrollment in the Phase 3 MAGNITUDE-2 trial of nexiguran ziclumeran for hereditary ATTR amyloidosis with polyneuropathy, exceeding the target of 60 randomized patients. The company also described commercial preparations for lonvoguran ziclumeran in hereditary angioedema, ahead of its March 10, 2027 FDA target action date. Approval remains pending.
Phillips Medisize announced an investment to acquire the complete footprint of its Chippenham site in England, strengthening its Global Inhalation Center of Excellence alongside Cambridge. Building on the 2025 Vectura acquisition, the site supports drug-device formulation development and early- and late-stage clinical supplies. The announcement links the investment to anticipated growth in complex inhaled therapies.
PharmAla signed an agreement with Corealis Pharma for ALA-002 drug-product development and GMP clinical supply. Corealis has begun formulation work in Laval, Québec, with an initial 50 mg capsule planned. Manufacturing of the first GMP batch is conditional on completing development activities. The agreement establishes a development and supply arrangement, rather than a product approval.
Nitto Denko Avecia and EnPlusOne signed an evaluation agreement for the ezRNA enzymatic synthesis platform. The phased program covers proof-of-concept studies, laboratory process evaluation, and technology transfer at Avecia facilities. The platform uses a water-based, template-free process. The agreement evaluates manufacturing feasibility; it does not announce a completed commercial manufacturing contract or a definitive platform license.
Precision BioSciences said an independent safety board endorsed additional dosing in the Phase 1/2 FUNCTION-DMD study after reviewing the first PBGENE-DMD recipient's eight-week observation period. No serious adverse events or adverse events of special interest were reported in that patient. The AAV-delivered gene-editing program remains investigational; this single-patient review does not establish efficacy or broader safety.
Precision BioSciences reported updated PBGENE-HBV Phase 1 data covering 25 patients and 59 administrations. The company described pgRNA loss and liver-biopsy evidence of cccDNA reduction at the expected go-forward dose of 0.4 mg/kg, with no dose-limiting toxicities reported. It plans Phase 2 evaluation, including assessment after nucleos(t)ide analog withdrawal; viral cure has not been established.
Ethris reported topline results from a randomized Phase 2a rhinovirus-challenge study involving 50 adults with asthma. A single nasal dose of ETH47, an interferon-lambda-encoding mRNA candidate, produced local expression and lower day-two viral load. Symptom improvements were described as numerical trends; exposure-response subgroup findings remain exploratory, without established clinical efficacy.
A Nature study describes FAST gene circuits that exploit cancer-associated ribosomal frameshifting to conditionally express gasdermin D and trigger pyroptosis. According to the original abstract, systemic AAV9 delivery produced tumor regression and immune activation in mouse colorectal and pancreatic cancer models, with synergy alongside checkpoint blockade. These are cell and animal findings, not human clinical evidence.
Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.
